

APPENDICES TO:

The effects of medical and non-medical cannabis use in older adults: protocol for a scoping review.

Wolfe DM et al.

- Appendix 1: PRISMA-P Checklist
- Appendix 2: Search Strategy
- Appendix 3: Sample tables for presentation of findings

Appendix 1. PRISMA-P Checklist

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Page #
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	NA
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	23
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	8
Support:			
Sources	5a	Indicate sources of financial or other support for the review	23
Sponsor	5b	Provide name for the review funder and/or sponsor	23
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	23
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	4–7
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	7
METHODS			

Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	8–12
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	12–13
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	29–39
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	14
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	13–17
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	18
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	18–20
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	10–11, 19–20
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	20
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	NA
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	NA
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	NA
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	20–21, 40–45
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	NA
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	NA

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

Appendix 2. Search Strategy

Cannabis
Final Strategy

Ovid Multifile

Database: Embase Classic+Embase <1947 to 2019 June 11>, Ovid MEDLINE(R) ALL <1946 to June 11, 2019>, PsycINFO <1806 to June Week 1 2019>

Search Strategy:

-
- 1 Cannabis/ (47483)
 - 2 exp Cannabinoids/ (82151)
 - 3 Marijuana Abuse/ (10406)
 - 4 exp "Marijuana Use"/ (14185)
 - 5 Marijuana Smoking/ (7532)
 - 6 ("c.indica" or "c.sativa" or cannabi* or bhang or cannador or cbd or charas or eucannabinolide* or ganja or ganjah or hash or hashish or hemp or marihuana* or marijuana*).tw,kf. (136291)
 - 7 (epidiolex or gwp 42003p or gwp42003p or nabidiolex).tw,kf. (165)
 - 8 (dronabinol or thc or tetrahydrocannabinol* or ea 1477 or ea1477 or marinol or qcd 84924 or syndros or tetrabinex or tetranabinex).tw,kf. (24947)
 - 9 (cesamet or nabilone).tw,kf. (979)
 - 10 (deltanyne or "abbott 40566" or namisol or dronabinolum or "QCD 84924" or "CCRIS 4726").tw,kf. (27)
 - 11 (nabiximol? or "gw 1000" or gw1000 or "sab 378" or sab378 or sativex).tw,kf. (1051)
 - 12 (13956-29-1 or 19GBJ60SN5 or UNII-19GBJ60SN5 or ZYN002).rn,nm. (4791)
 - 13 or/1-12 [CANNABIS] (170422)
 - 14 exp Animals/ not (exp Animals/ and Humans/) (18640406)
 - 15 13 not 14 [ANIMAL-ONLY REMOVED] (107451)
 - 16 (comment or editorial or news or newspaper article).pt. (1925110)
 - 17 (letter not (letter and randomized controlled trial)).pt. (2094822)
 - 18 (case reports not (meta analysis or systematic review or controlled clinical trial or randomized controlled trial or pragmatic clinical trial or comparative study or observational study)).pt. (2003526)
 - 19 (case report* or case study or case studies).ti. not (meta analysis or systematic review or controlled clinical trial or randomized controlled trial or pragmatic clinical trial or comparative study or observational study).pt. (663973)
 - 20 15 not (16 or 17 or 18 or 19) [OPINION PIECES AND CASE REPORTS REMOVED] (100750)
 - 21 limit 20 to yr="2000-current" (73251)
 - 22 limit 21 to systematic reviews [Limit not valid in Embase; records were retained] (27329)
 - 23 meta analysis.pt. (101732)
 - 24 exp meta-analysis as topic/ (57757)
 - 25 (meta-analy* or metanaly* or metaanaly* or met analy* or integrative research or integrative review* or integrative overview* or research integration or research overview* or collaborative review*).tw,kf. (390079)
 - 26 systematic review.pt. (107850)
 - 27 (systematic review* or systematic overview* or evidence-based review* or evidence-based overview* or (evidence adj3 (review* or overview*)) or meta-review* or meta-overview* or meta-synthes* or "review of reviews" or technology assessment* or HTA or HTAs).tw,kf. (463074)
 - 28 exp Technology assessment, biomedical/ (24267)
 - 29 (cochrane or health technology assessment or evidence report).jw. (38382)
 - 30 (network adj (MA or MAs)).tw,kf. (22)

31 (NMA or NMAs).tw,kf. (4839)
32 indirect* compar*.tw,kf. (5074)
33 (indirect treatment* adj1 compar*).tw,kf. (743)
34 (mixed treatment* adj1 compar*).tw,kf. (1323)
35 (multiple treatment* adj1 compar*).tw,kf. (373)
36 (multi-treatment* adj1 compar*).tw,kf. (5)
37 simultaneous* compar*.tw,kf. (2469)
38 mixed comparison?.tw,kf. (69)
39 or/23-38 (799947)
40 21 and 39 (1997)
41 22 or 40 [SRs/MAs] (27931)
42 (controlled clinical trial or randomized controlled trial or pragmatic clinical trial).pt. (572176)
43 clinical trials as topic.sh. (187251)
44 exp Randomized Controlled Trials as Topic/ (288357)
45 (randomi#ed or randomly or RCT or placebo*).tw,kf. (2334678)
46 ((singl* or doubl* or trebl* or tripl*) adj (mask* or blind* or dumm*)).tw,kf. (420279)
47 trial.ti. (507909)
48 or/42-47 (2953906)
49 21 and 48 [RCTS] (5693)
50 controlled clinical trial.pt. (93106)
51 Controlled Clinical Trial/ or Controlled Clinical Trials as Topic/ (570170)
52 (control* adj2 trial*).tw,kf. (616820)
53 Non-Randomized Controlled Trials as Topic/ (10630)
54 (nonrandom* or non-random* or quasi-random* or quasi-experiment*).tw,kf. (132402)
55 (nRCT or nRCT or non-RCT).tw,kf. (710)
56 Controlled Before-After Studies/ (214313)
57 (control* adj3 ("before and after" or "before after")).tw,kf. (10168)
58 Interrupted Time Series Analysis/ (206520)
59 time series.tw,kf. (66339)
60 (pre- adj3 post-).tw,kf. (235905)
61 (pretest adj3 posttest).tw,kf. (18124)
62 Historically Controlled Study/ (224681)
63 (control* adj2 stud\$3).tw,kf. (541007)
64 Control Groups/ (125963)
65 (control* adj2 group\$1).tw,kf. (1235605)
66 trial.ti. (507909)
67 or/50-66 (3428538)
68 21 and 67 [NON-RCTS] (5249)
69 exp Cohort Studies/ (2337056)
70 cohort?.tw,kf. (1462096)
71 Retrospective Studies/ (1166307)
72 (longitudinal or prospective or retrospective).tw,kf. (3106077)
73 ((followup or follow-up) adj (study or studies)).tw,kf. (130193)
74 Observational study.pt. (62773)
75 (observation\$2 adj (study or studies)).tw,kf. (252177)
76 ((population or population-based) adj (study or studies or analys#s)).tw,kf. (40902)
77 ((multidimensional or multi-dimensional) adj (study or studies)).tw,kf. (371)
78 Comparative Study.pt. (1831731)
79 ((comparative or comparison) adj (study or studies)).tw,kf. (263134)
80 exp Case-Control Studies/ (1156584)
81 ((case-control* or case-based or case-comparison) adj (study or studies)).tw,kf. (233233)

- 82 Cross-Sectional Studies/ (470673)
83 (cross-section* or crosssection*).tw,kf. (872615)
84 or/69-83 (8133205)
85 21 and 84 [OBSERVATIONAL STUDIES] (16552)
86 Qualitative Research/ (119259)
87 Interview/ (220812)
88 interview*.mp. (1208372)
89 (theme* or thematic).mp. (343144)
90 qualitative.af. (889955)
91 Nursing Methodology Research/ (30884)
92 questionnaire*.mp. (1946523)
93 ethnological research.mp. (29)
94 ethnograph*.mp. (49253)
95 ethnosing.af. (363)
96 phenomenol*.af. (165043)
97 (grounded adj (theor* or study or studies or research or analys#s)).af. (78144)
98 (life stor* or women* stor*).mp. (6740)
99 (emic or etic or hermeneutic* or heuristic* or semiotic*).af. or (data adj1 saturat*).tw. or participant observ*.tw. (141504)
100 (social construct* or (postmodern* or post-structural*) or (post structural* or poststructural*) or post modern* or post-modern* or feminis* or interpret*).mp. (1234463)
101 (action research or cooperative inquir* or co operative inquir* or co-operative inquir*).mp. (17587)
102 (humanistic or existential or experiential or paradigm*).mp. (453321)
103 (field adj (study or studies or research)).tw. (43603)
104 human science.tw. (1161)
105 biographical method.tw. (103)
106 theoretical sampl*.af. (2386)
107 ((purpos* adj4 sampl*) or (focus adj group*)).af. (187736)
108 (account or accounts or unstructured or open-ended or open ended or text* or narrative*).mp. (1691731)
109 (life world or life-world or conversation analys#s or personal experience* or theoretical saturation).mp. (83460)
110 ((lived or life) adj experience*).mp. (67584)
111 observational method*.af. (4965)
112 content analys#s.af. (111618)
113 (constant adj (comparative or comparison)).af. (14795)
114 ((discourse* or discours*) adj3 analys#s).tw. (13049)
115 narrative analys#s.af. (9134)
116 (heidegger* or colaizzi* or spiegelberg* or van manen* or van kaam* or merleau ponty* or husserl* or foucault* or (corbin adj2 strauss*) or glaser*).tw. (17480)
117 mixed method*.tw,kf. (59378)
118 or/86-117 (6729977)
119 21 and 118 [QUALITATIVE STUDIES] (18936)
120 41 or 49 or 68 or 85 or 119 [ALL STUDY DESIGNS] (51581)
121 120 use medall [MEDLINE RECORDS] (15274)
122 cannabis/ (47483)
123 exp cannabinoid/ (69089)
124 cannabis addiction/ (9169)
125 exp "cannabis use"/ (9827)
126 cannabis addiction/ (9169)

- 127 cannabis sativa/ (8702)
- 128 ("c.indica" or "c.sativa" or cannabi* or bhang or cannador or cbd or charas or eucannabinolide* or ganja or ganjah or hash or hashish or hemp or marihuana* or marijuana*).tw,kw. (137411)
- 129 (epidiolex or gwp 42003p or gwp42003p or nabidiolex).tw,kw. (165)
- 130 (dronabinol or thc or tetrahydrocannabinol* or ea 1477 or ea1477 or marinol or qcd 84924 or syndros or tetrabinex or tetranabinex).tw,kw. (25260)
- 131 (cesamet or nabilone).tw,kw. (993)
- 132 (deltanyne or "abbott 40566" or namisol or dronabinolum or "QCD 84924" or "CCRIS 4726").tw,kw. (27)
- 133 (nabiximol? or "gw 1000" or gw1000 or "sab 378" or sab378 or sativex).tw,kw. (1065)
- 134 (13956-29-1 or 19GBJ60SN5 or UNII-19GBJ60SN5 or ZYN002).rn. (4791)
- 135 or/122-134 [CANNABIS] (170167)
- 136 exp animal/ or exp animal experimentation/ or exp animal model/ or exp animal experiment/ or nonhuman/ or exp vertebrate/ (50765399)
- 137 exp human/ or exp human experimentation/ or exp human experiment/ (38848166)
- 138 136 not 137 (11918927)
- 139 135 not 138 [ANIMAL-ONLY REMOVED] (137727)
- 140 editorial.pt. (1097387)
- 141 letter.pt. not (letter.pt. and randomized controlled trial/) (2089753)
- 142 (case report* or case study or case studies).ti. not (meta-analysis/ or "systematic review"/ or randomized controlled trial/ or controlled clinical trial/ or controlled study/ or time series analysis/ or cohort analysis/ or retrospective study/ or longitudinal study/ or prospective study/ or exp comparative study/ or observational study/ or exp case control study/ or cross-sectional study/) (647181)
- 143 conference abstract.pt. (3430116)
- 144 139 not (140 or 141 or 142 or 143) [OPINION PIECES, CASE REPORTS AND CONFERENCE ABSTRACTS REMOVED] (119468)
- 145 limit 144 to yr="2000-current" (92402)
- 146 meta-analysis/ (270155)
- 147 "systematic review"/ (314772)
- 148 "meta analysis (topic)"/ (39946)
- 149 (meta-analy* or metanaly* or metaanaly* or met analy* or integrative research or integrative review* or integrative overview* or research integration or research overview* or collaborative review*).tw,kw. (393014)
- 150 (systematic review* or systematic overview* or evidence-based review* or evidence-based overview* or (evidence adj3 (review* or overview*)) or meta-review* or meta-overview* or meta-synthes* or "review of reviews" or technology assessment* or HTA or HTAs).tw,kw. (466451)
- 151 biomedical technology assessment/ (23156)
- 152 (cochrane or health technology assessment or evidence report).jw. (38382)
- 153 (network adj (MA or MAs)).tw,kw. (22)
- 154 (NMA or NMAs).tw,kw. (4857)
- 155 indirect* compar*.tw,kw. (5140)
- 156 (indirect treatment* adj1 compar*).tw,kw. (747)
- 157 (mixed treatment* adj1 compar*).tw,kw. (1347)
- 158 (multiple treatment* adj1 compar*).tw,kw. (379)
- 159 (multi-treatment* adj1 compar*).tw,kw. (5)
- 160 simultaneous* compar*.tw,kw. (2469)
- 161 mixed comparison?.tw,kw. (70)
- 162 or/146-161 (866096)
- 163 145 and 162 [REVIEWS] (3255)
- 164 randomized controlled trial/ or controlled clinical trial/ (1311919)
- 165 "clinical trial (topic)"/ (101825)

- 166 "randomized controlled trial (topic)"/ (161519)
167 (randomi#ed or randomly or RCT or placebo*).tw,kw. (2336720)
168 ((singl* or doubl* or trebl* or tripl*) adj (mask* or blind* or dumm*)).tw,kw. (420435)
169 trial.ti. (507909)
170 or/164-169 (3096931)
171 145 and 170 [RCTS] (8046)
172 controlled clinical trial/ (556323)
173 "controlled clinical trial (topic)"/ (10128)
174 (control* adj2 trial*).tw,kw. (620815)
175 (nonrandom* or non-random* or quasi-random* or quasi-experiment*).tw,kw. (132629)
176 (nRCT or nRCT or non-RCT).tw,kw. (711)
177 (control* adj3 ("before and after" or "before after")).tw,kw. (10173)
178 time series analysis/ (23336)
179 time series.tw,kw. (67114)
180 pretest posttest control group design/ (388)
181 (pre- adj3 post-).tw,kw. (235933)
182 (pretest adj3 posttest).tw,kw. (18127)
183 controlled study/ (6713848)
184 (control* adj2 stud\$3).tw,kw. (542508)
185 control group/ (125963)
186 (control* adj2 group\$1).tw,kw. (1235369)
187 trial.ti. (507909)
188 or/172-187 (8856567)
189 145 and 188 [NON-RCTS] (17004)
190 cohort analysis/ (714392)
191 cohort?.tw,kw. (1464380)
192 retrospective study/ (1537235)
193 longitudinal study/ (250984)
194 prospective study/ (1031600)
195 (longitudinal or prospective or retrospective).tw,kw. (3111465)
196 follow up/ (1448744)
197 ((followup or follow-up) adj (study or studies)).tw,kw. (132011)
198 observational study/ (231986)
199 (observation\$2 adj (study or studies)).tw,kw. (252792)
200 population research/ (99974)
201 ((population or population-based) adj (study or studies or analys#s)).tw,kw. (48926)
202 ((multidimensional or multi-dimensional) adj (study or studies)).tw,kw. (372)
203 exp comparative study/ (3194802)
204 ((comparative or comparison) adj (study or studies)).tw,kw. (261543)
205 exp case control study/ (1156584)
206 ((case-control* or case-based or case-comparison) adj (study or studies)).tw,kw. (234698)
207 cross-sectional study/ (598245)
208 (cross-section* or crosssection*).tw,kw. (874654)
209 or/190-208 (10058649)
210 145 and 209 [OBSERVATIONAL STUDIES] (23782)
211 exp qualitative research/ (125102)
212 exp interview/ (285894)
213 interview*.mp. (1208372)
214 (theme* or thematic).mp. (343144)
215 qualitative.af. (889955)
216 nursing methodology research/ (30884)

- 217 questionnaire*.mp. (1946523)
218 ethnological research.mp. (29)
219 ethnograph*.mp. (49253)
220 ethn nursing.af. (363)
221 phenomenol*.af. (165043)
222 (grounded adj (theor* or study or studies or research or analys#s)).af. (78144)
223 (life stor* or women* stor*).mp. (6740)
224 (emic or etic or hermeneutic* or heuristic* or semiotic*).af. or (data adj1 saturat*).tw. or participant observ*.tw. (141504)
225 (social construct* or (postmodern* or post-structural*) or (post structural* or poststructural*) or post modern* or post-modern* or feminis* or interpret*).mp. (1234463)
226 (action research or cooperative inquir* or co operative inquir* or co-operative inquir*).mp. (17587)
227 (humanistic or existential or experiential or paradigm*).mp. (453321)
228 (field adj (study or studies or research)).tw. (43603)
229 human science.tw. (1161)
230 biographical method.tw. (103)
231 theoretical sampl*.af. (2386)
232 ((purpos* adj4 sampl*) or (focus adj group*)).af. (187736)
233 (account or accounts or unstructured or open-ended or open ended or text* or narrative*).mp. (1691731)
234 (life world or life-world or conversation analys#s or personal experience* or theoretical saturation).mp. (83460)
235 ((lived or life) adj experience*).mp. (67584)
236 observational method*.af. (4965)
237 content analys#s.af. (111618)
238 (constant adj (comparative or comparison)).af. (14795)
239 ((discourse* or discours*) adj3 analys#s).tw. (13049)
240 narrative analys#s.af. (9134)
241 (heidegger* or colaizzi* or spiegelberg* or van manen* or van kaam* or merleau ponty* or husserl* or foucault* or (corbin adj2 strauss*) or glaser*).tw. (17480)
242 mixed method*.tw,kw. (59805)
243 or/211-242 (6739667)
244 145 and 243 [QUALITATIVE STUDIES] (23300)
245 163 or 171 or 189 or 210 or 244 [ALL STUDY DESIGNS] (50209)
246 245 use emczd [EMBASE RECORDS] (25229)
247 exp Cannabis/ (50168)
248 exp Cannabinoids/ (82151)
249 Marijuana Usage/ (2717)
250 ("c.indica" or "c.sativa" or cannabi* or bhang or cannador or cbd or charas or eucannabinolide* or ganja or ganjah or hash or hashish or hemp or marihuana* or marijuana*).tw. (135754)
251 (epidiox or gwp 42003p or gwp42003p or nabidiox).tw. (164)
252 (dronabinol or thc or tetrahydrocannabinol* or ea 1477 or ea1477 or marinol or qcd 84924 or syndros or tetrabinex or tetranabinex).tw. (24784)
253 (cesamet or nabilone).tw. (975)
254 (deltanyne or "abbott 40566" or namisol or dronabinolum or "QCD 84924" or "CCRIS 4726").tw. (26)
255 (nabiximol? or "gw 1000" or gw1000 or "sab 378" or sab378 or sativex).tw. (1040)
256 or/247-255 [CANNABIS] (167465)
257 limit 256 to yr="2000-current" (130951)

- 258 limit 257 to ("0830%2509%2509systematic review" or 1200 meta analysis or 1300 metasynthesis) [Limit not valid in Embase,Ovid MEDLINE(R),Ovid MEDLINE(R) Daily Update,Ovid MEDLINE(R) In-Process,Ovid MEDLINE(R) Publisher,PsycINFO; records were retained] (111540)
- 259 meta analysis/ (270155)
- 260 (meta-analy* or metanaly* or metaanaly* or met analy* or integrative research or integrative review* or integrative overview* or research integration or research overview* or collaborative review*).tw. (388820)
- 261 "systematic review"/ (314772)
- 262 (systematic review* or systematic overview* or evidence-based review* or evidence-based overview* or (evidence adj3 (review* or overview*)) or meta-review* or meta-overview* or meta-synthes* or "review of reviews" or technology assessment* or HTA or HTAs).tw. (461287)
- 263 (network adj (MA or MAs)).tw. (22)
- 264 (NMA or NMAs).tw. (4824)
- 265 indirect* compar*.tw. (5052)
- 266 (indirect treatment* adj1 compar*).tw. (725)
- 267 (mixed treatment* adj1 compar*).tw. (1267)
- 268 (multiple treatment* adj1 compar*).tw. (360)
- 269 (multi-treatment* adj1 compar*).tw. (5)
- 270 simultaneous* compar*.tw. (2469)
- 271 mixed comparison?.tw. (69)
- 272 or/259-271 (811715)
- 273 257 and 272 (3419)
- 274 258 or 273 [REVIEWS] (111936)
- 275 limit 257 to "0300 clinical trial" [Limit not valid in Embase,Ovid MEDLINE(R),Ovid MEDLINE(R) Daily Update,Ovid MEDLINE(R) In-Process,Ovid MEDLINE(R) Publisher; records were retained] (111666)
- 276 exp clinical trials/ (307124)
- 277 (randomi#ed or randomly or RCT or placebo*).tw. (2332689)
- 278 ((singl* or doubl* or trebl* or tripl*) adj (mask* or blind* or dumm*)).tw. (420183)
- 279 trial.ti. (507909)
- 280 or/276-279 (2730358)
- 281 257 and 280 (9191)
- 282 275 or 281 [RCTS] (112919)
- 283 (control* adj2 trial*).tw. (614352)
- 284 (nonrandom* or non-random* or quasi-random* or quasi-experiment*).tw. (132248)
- 285 (nRCT or nRCT or non-RCT).tw. (709)
- 286 (control* adj3 ("before and after" or "before after")).tw. (10162)
- 287 time series/ (23361)
- 288 time series.tw. (65880)
- 289 (pre- adj3 post-).tw. (235815)
- 290 (pretest adj3 posttest).tw. (18118)
- 291 (control* adj2 stud\$3).tw. (540018)
- 292 experiment controls/ (907)
- 293 (control* adj2 group\$1).tw. (1235251)
- 294 trial.ti. (507909)
- 295 or/283-294 (2833768)
- 296 257 and 295 [NON-RCTS] (7783)
- 297 limit 257 to ("0430 followup study" or "0450 longitudinal study" or "0451 prospective study" or "0453 retrospective study") [Limit not valid in Embase,Ovid MEDLINE(R),Ovid MEDLINE(R) Daily Update,Ovid MEDLINE(R) In-Process,Ovid MEDLINE(R) Publisher; records were retained] (113931)
- 298 cohort?.tw. (1460179)

- 299 exp longitudinal studies/ (267415)
 300 retrospective studies/ (1166307)
 301 (longitudinal or prospective or retrospective).tw. (3101143)
 302 followup studies/ (627480)
 303 ((followup or follow-up) adj (study or studies)).tw. (128839)
 304 exp observation methods/ (5724)
 305 (observation\$2 adj (study or studies)).tw. (251407)
 306 ((population or population-based) adj (study or studies or analys#s)).tw. (40364)
 307 ((multidimensional or multi-dimensional) adj (study or studies)).tw. (371)
 308 ((comparative or comparison) adj (study or studies)).tw. (258365)
 309 ((case-control* or case-based or case-comparison) adj (study or studies)).tw. (232321)
 310 (cross-section* or crosssection*).tw. (871622)
 311 or/298-310 (6229379)
 312 257 and 311 (21156)
 313 297 or 312 [OBSERVATIONAL STUDIES] (116189)
 314 interview*.mp. (1208372)
 315 thematic analysis/ (12832)
 316 qualitative.af. (889955)
 317 questionnaire*.mp. (1946523)
 318 ethnological research.mp. (29)
 319 ethnograph*.mp. (49253)
 320 ethnosing.af. (363)
 321 phenomenol*.af. (165043)
 322 grounded theory/ (10853)
 323 (grounded adj (theor* or study or studies or research or analys#s)).af. (78144)
 324 exp life experiences/ (51768)
 325 (life stor* or women* stor*).mp. (6740)
 326 (emic or etic or hermeneutic* or heuristic* or semiotic*).af. or (data adj1 saturat*).tw. or participant observ*.tw. (141504)
 327 (social construct* or (postmodern* or post-structural*) or (post structural* or poststructural*) or post modern* or post-modern* or feminis* or interpret*).mp. (1234463)
 328 (action research or cooperative inquir* or co operative inquir* or co-operative inquir*).mp. (17587)
 329 (humanistic or existential or experiential or paradigm*).mp. (453321)
 330 (field adj (study or studies or research)).tw. (43603)
 331 human science.tw. (1161)
 332 biographical method.tw. (103)
 333 theoretical sampl*.af. (2386)
 334 ((purpos* adj4 sampl*) or (focus adj group*)).af. (187736)
 335 (account or accounts or unstructured or open-ended or open ended or text* or narrative*).mp. (1691731)
 336 (life world or life-world or conversation analys#s or personal experience* or theoretical saturation).mp. (83460)
 337 ((lived or life) adj experience*).mp. (67584)
 338 observational method*.af. (4965)
 339 content analys#s.af. (111618)
 340 (constant adj (comparative or comparison)).af. (14795)
 341 ((discourse* or discours*) adj3 analys#s).tw. (13049)
 342 narrative analys#s.af. (9134)
 343 (heidegger* or colaizzi* or spiegelberg* or van manen* or van kaam* or merleau ponty* or husserl* or foucault* or (corbin adj2 strauss*) or glaser*).tw. (17480)

344 mixed method*.tw. (59032)
345 or/314-344 (6636676)
346 257 and 345 [QUALITATIVE STUDIES] (26698)
347 274 or 282 or 296 or 313 or 346 [ALL STUDY DESIGNS] (122411)
348 347 use medall,emczd (111415)
349 347 not 348 [PSYCINFO RECORDS] (10996)
350 121 or 246 or 349 [ALL STUDY DESIGNS - ALL DATABASES] (51499)
351 41 use medall [MEDLINE REVIEWS] (1327)
352 163 use emczd [EMBASE REVIEWS] (1765)
353 274 use medall,emczd (111415)
354 274 not 353 [PSYCINFO REVIEWS] (521)
355 351 or 352 or 354 [REVIEWS - ALL DATABASES] (3613)
356 remove duplicates from 355 (2316) [TOTAL UNIQUE REVIEWS]
357 356 use medall [MEDLINE UNIQUE REVIEWS] (1314)
358 356 use emczd [EMBASE UNIQUE REVIEWS] (853)
359 356 not (357 or 358) [PSYCINFO UNIQUE REVIEWS] (149)
360 49 use medall [MEDLINE RCTS] (2766)
361 171 use emczd [EMBASE RCTS] (4104)
362 282 use medall,emczd (111415)
363 282 not 362 [PSYCINFO RCTS] (1504)
364 360 or 361 or 363 [RCTS - ALL DATABASES] (8374)
365 limit 364 to yr="2012-current" (4981)
366 remove duplicates from 365 (2954)
367 364 not 365 (3393)
368 remove duplicates from 367 (2013)
369 366 or 368 [TOTAL UNIQUE RCTS] (4967)
370 369 use medall [MEDLINE UNIQUE RCTS] (2751)
371 369 use emczd [EMBASE UNIQUE RCTS] (1881)
372 369 not (370 or 371) [PSYCINFO UNIQUE RCTS] (335)
373 68 use medall [MEDLINE NRCTS] (2156)
374 189 use emczd [EMBASE NRCTS] (13613)
375 296 use medall,emczd (6496)
376 296 not 375 [PSYCINFO NRCTS] (1287)
377 373 or 374 or 376 [NRCTS - ALL DATABASES] (17056)
378 85 use medall [MEDLINE OBSERVATIONAL STUDIES] (9014)
379 210 use emczd [EMBASE OBSERVATIONAL STUDIES] (11318)
380 313 use medall,emczd (111415)
381 313 not 380 [PSYCINFO OBSERVATIONAL STUDIES] (4774)
382 378 or 379 or 381 [OBSERVATIONAL STUDIES - ALL DATABASES] (25106)
383 377 or 382 [NRCTS, OBSERVATIONAL STUDIES - ALL DATABASES] (35890)
384 limit 383 to yr="2018-current" (5258)
385 remove duplicates from 384 (3489)
386 limit 383 to yr="2016-2017" (5786)
387 remove duplicates from 386 (3556)
388 limit 383 to yr="2014-2015" (5227)
389 remove duplicates from 388 (3216)
390 limit 383 to yr="2012-2013" (4289)
391 remove duplicates from 390 (2631)
392 limit 383 to yr="2009-2011" (5305)
393 remove duplicates from 392 (3349)
394 limit 383 to yr="2005-2008" (5699)

395 remove duplicates from 394 (3749)
 396 limit 383 to yr="2000-2004" (4326)
 397 remove duplicates from 396 (2919)
 398 385 or 387 or 389 or 391 or 393 or 395 or 397 [TOTAL UNIQUE NRCTS, OBSERVATIONAL STUDIES] (22909)
 399 398 use medall [MEDLINE UNIQUE NRCTS, OBSERVATIONAL STUDIES] (10253)
 400 398 use emczd [EMBASE UNIQUE NRCTS, OBSERVATIONAL STUDIES] (11250)
 401 398 not (399 or 400) [PSYCINFO UNIQUE NRCTS, OBSERVATIONAL STUDIES] (1406)
 402 119 use medall [MEDLINE QUALITATIVE STUDIES] (6892)
 403 244 use emczd [EMBASE QUALITATIVE STUDIES] (9063)
 404 346 use medall,emczd (18959)
 405 346 not 404 [PSYCINFO QUALITATIVE STUDIES] (7739)
 406 402 or 403 or 405 [QUALITATIVE STUDIES - ALL DATABASES] (23694)
 407 limit 406 to yr="2017-current" (4897)
 408 remove duplicates from 407 (3033)
 409 limit 406 to yr="2014-2016" (5456)
 410 remove duplicates from 409 (3388)
 411 limit 406 to yr="2010-2013" (5531)
 412 remove duplicates from 411 (3350)
 413 limit 406 to yr="2005-2009" (4995)
 414 remove duplicates from 413 (3056)
 415 limit 406 to yr="2000-2004" (2816)
 416 remove duplicates from 415 (1737)
 417 408 or 410 or 412 or 414 or 416 [TOTAL UNIQUE QUALITATIVE STUDIES - ALL DATABASES] (14563)
 418 417 use medall [MEDLINE UNIQUE QUALITATIVE STUDIES] (6877)
 419 417 use emczd [EMBASE UNIQUE QUALITATIVE STUDIES] (3597)
 420 417 not (418 or 419) [PSYCINFO UNIQUE QUALITATIVE STUDIES] (4089)

Cochrane Library

<https://www-cochranelibrary-com.proxy.bib.uottawa.ca/advanced-search/search-manager?search=3084048>

Search Name: Cannabis - Final
 Date Run: 13/06/2019 01:27:59
 Comment: OHRI - 2019 Jun 12

ID	Search Hits
#1	[mh Cannabis] 290
#2	[mh Cannabinoids] 731
#3	[mh "Marijuana Abuse"] 524
#4	[mh "Marijuana Use"] 284
#5	[mh "Marijuana Smoking"] 276
#6	("c.indica" or "c.sativa" or cannabi* or bhang or cannador or cbd or charas or eucannabinolide* or ganja or ganjah or hash or hashish or hemp or marihuana* or marijuana*):ti,ab,kw 4028
#7	(epidiolex or gwp 42003p or gwp42003p or nabidiolex):ti,ab,kw 30
#8	(dronabinol or thc or tetrahydrocannabinol* or ea 1477 or ea1477 or marinol or qcd 84924 or syndros or tetrabinex or tetranabinex):ti,ab,kw 1387

- #9 (cesamet or nabilone):ti,ab,kw 142
#10 (deltanyne or "abbott 40566" or namisol or dronabinolum or "QCD 84924" or "CCRIS 4726"):ti,ab,kw 16
#11 (nabiximol* or "gw 1000" or gw1000 or "sab 378" or sab378 or sativex):ti,ab,kw 167
#12 {or #1-#11} with Publication Year from 2000 to 2019, in Trials 3638
#13 {or #1-#11} in Cochrane Reviews, Cochrane Protocols 45
#14 #12 OR #13 3683

Reviews – 42

Protocols – 3

Trials – 3638

Appendix 3. Sample tables for presentation of findings**Table 1. Sample table depicting the presence/absence of demographic subgroups in observational studies.**

Study	Age groups			Sex/gender			Race/ethnicity						Marital status					Employment status			Accommodation status			Residential setting				
	50-64	65-74	75+	Men	Women	Other	Caucasian	Black	Indigenous	Asian	Other	NR	Married	Single	Divorced	Widowed	NR	Retired	Working	NR	Alone	Shared	NR	Community	Retirement	LTC	NR	
Lee et al., 2012																												
Smith et al., 2017																												

Table 2. Sample table depicting the presence/absence of comorbidities and co-use in observational studies

Study	Mental health comorbidities							Physical comorbidities					Co-use			
	Anxiety	Depression	Insomnia	Schizophrenia	Cognitive decline	PTSD	NR	Cancer	Chronic pain	Diabetes	Multiple sclerosis	NR	Prescribed drugs	Illicit drugs	No co-use	NR
Lee et al., 2012																
Smith et al., 2017																

Table 3. Sample table of types of cannabis use, products, and modes of consumption in observational studies

Study	Cannabis use				Cannabis product			Mode of consumption				
	Medical	Non-medical	Mixed	NR	Natural	Synthetic	NR	Smoking	Vaporizing	Edibles	Oils	NR
Lee et al., 2012												
Smith et al., 2017												

Table 4. Sample table of types of comparisons evaluated in primary studies

Study	Comparison evaluated					
	Use-only (single-arm study)	Use vs no use	Frequency of use	Strain type	Concentration of THC or CBD	Mode of consumption
Lee et al., 2012						
Smith et al., 2017						

Table 5. Sample table of all outcomes and direction of effects for observational studies. This table will likely be split into four, tables depending on outcomes reported: mental health/behavioural, physical health, brain, and pharmacokinetic outcomes. Green cells indicate a positive effect, red cells a negative effect, and grey cells a non-significant effect was found. Blank/white cells indicate an outcome was not measured.

Study and comparison (Reference group is listed second)	Mental health/behavioural						Physical health				Brain outcomes						Pharmacokinetic outcomes		
	Anxiety	Depression	Manic/ suicidal behaviour	Paranoia	Risky behaviour	New substance use disorder	Chronic pain	Car accidents	Falls	ED visits	Gray matter	White matter integrity	Functional connectivity	Cortical thickness	Total volume	Regional volumes	Surface morphometry/shape	Interactions with prescription drugs	Interactions with illicit drugs
Lee et al., 2012 Use vs no use	Green	Green	Grey	White	White	Green	Grey	White	White	Grey	White	White	White	White	White	White	White	White	White
Lee et al., 2012 High vs low conc of THC	Green	Green	Green	White	White	Green	Grey	White	White	Green	White	White	White	White	White	White	White	White	White
Lee et al., 2012	Grey	Grey	Grey	White	White	Grey	Grey	White	White	Grey	White	White	White	White	White	White	White	White	White

Study and comparison	Reference group is listed second)	Smoking vs vaping	Smith et al., 2017	Daily vs weekly use	Smith et al., 2017	High vs low conc of THC
Mental health/behavioural	Anxiety					
	Depression					
	Manic/ suicidal behaviour					
	Paranoia					
	Risky behaviour					
	New substance use disorder					
Physical health	Chronic pain					
	Car accidents					
	Falls					
	ED visits					
Brain outcomes	Gray matter					
	White matter integrity					
	Functional connectivity					
	Cortical thickness					
	Total volume					
	Regional volumes					
	Surface morphometry/shape					
Pharmacokinetic outcomes	Interactions with prescription drugs					
	Interactions with illicit drugs					

Wolfe D, et al. *BMJ Open* 2020; 10:e034301. doi: 10.1136/bmjopen-2019-034301